Predict your next investment

Private Equity
industrial-investors.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

About Industrial Investors Group

Industrial Investors is a private equity financing firm.

Industrial Investors Group Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Industrial Investors Group News

With $50M round, Peninsula biotech bets on next-generation cancer drug combos

Feb 10, 2016

Armed with $50 million from the former Google Ventures, Celgene Corp. and others, a young Redwood City biotech company is aiming to pair its drug with other drugs that rev up the immune system to destroy cancer cells. ARMO BioSciences Inc. said Wednesday that the Series C round from Alphabet Inc.'s (NASDAQ: GOOG) GV venture capital arm (the former Google Ventures), Celgene (NASDAQ: CELG), HBM Healthcare Investments, Industrial Investors Group and Clough Investment Partners will help it move into more-definitive studies by early next year. Those funders joined with existing investors Kleiner Perkins Caufield & Byers , OrbiMed, DAG Ventures and NanoDimension to push ARMO's total fundraising since 2012 to $100 million. ARMO's lead drug, called AM-0010, has shown promise as a potential standalone therapy, said President and CEO Peter Van Vlasselaer . But its real power, he said, is combining it with other drugs that reset the immune system to attack a wide range of cancers. So-called cancer immunotherapy is a hot area of work among commercial biotech companies. Immunotherapy drugs put the body's own immune system on high alert, helping it spot the proteins that tumors secrete to put the brakes on the immune system. The knock on early cancer immunotherapy drugs is that they tend to hop up the immune system to the point that patients develop autoimmune diseases, such as rheumatoid arthritis. ARMO has three Phase Ib trials in lung and kidney cancers as well as melanoma that combine AM-0010 with a group of checkpoint inhibitors, known as anti-PD-1s, which unlock the brakes that cancers trick the immune system into applying. Anti-PD-1 stands for anti-programmed cell death protein. ARMO also has two ongoing studies of AM-0010 in combination with chemotherapies in pancreatic cancer and triple-negative breast cancer. Other companies are working on drugs that target other tumor-secreted proteins, such as CTLA-4. AstraZeneca, for example, earlier this week said the combination of its drug with the CTLA-4 treatment tremelimumab was successful in a small study of non-small cell lung cancer patients whose cancer had spread. South San Francisco-based biotech lord Genentech Inc. also is studying its immunotherapy agents alone and in combination with other companies' drugs. The key for 11-employee ARMO is that AM-0010 is an extended-play version of the cell-signaling protein interleukin-10, or IL-10. Because the drug is pegylated — extending its "half life" in the blood — it seems to trigger T cells that are integral parts of the immune system's attack on foreign invaders. In other words, ARMO's recombinant human IL-10 therapy seems to prime tumors and accelerate the immune system's recognition of the PD-1 protein on the cell surface. "We think that by giving an anti-PD-1 on top of the IL-10, you see it go faster to effectors" — the immune system's scouts — Van Vlasselaer said. "You're blocking T cells from going into quiescent mode. " ARMO also has an early-stage trial of AM-0010 and an anti-PD-1 against melanoma. ARMO, meanwhile, is working on its own anti-PD-1 drug, licensed in the fall from Open Monoclonal Technology Inc. That drug could be in the clinic next year, Van Vlasselaer said, and then quickly move to studies in combination with AM-0010. "What we believe is that in the immuno-oncology space, it's important to have molecules that are affecting the immune suppression milieu of the tumor and eliciting immune responses to the tumor and causing tumors to be more immune-sensitive," Van Vlasselaer said. "The question is, who has that 'other' molecule to use in addition to the anti-PD-1 — and we think we have that. " Ron covers biotech and sports business. Related Content

Industrial Investors Group Investments

6 Investments

Industrial Investors Group has made 6 investments. Their latest investment was in Amphivena Therapeutics as part of their Series C on December 12, 2018.

CBI Logo

Industrial Investors Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/19/2018

Series C

Amphivena Therapeutics

$62M

Yes

7

2/25/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

2/10/2016

Series C

Subscribe to see more

$99M

Subscribe to see more

10

6/16/2015

Series E

Subscribe to see more

$99M

Subscribe to see more

10

7/10/2013

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/19/2018

2/25/2016

2/10/2016

6/16/2015

7/10/2013

Round

Series C

Seed VC

Series C

Series E

Series D

Company

Amphivena Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$62M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

10

10

10

10

Industrial Investors Group Portfolio Exits

1 Portfolio Exit

Industrial Investors Group has 1 portfolio exit. Their latest portfolio exit was ARMO BioSciences on January 26, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/26/2018

IPO

$99M

3

Date

1/26/2018

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

3

Industrial Investors Group Team

6 Team Members

Industrial Investors Group has 6 team members, including current President, Sergey V. Generalov.

Name

Work History

Title

Status

Sergey V. Generalov

President

Current

Maxim Likhachev

Senior Vice President

Current

Eugene Andratchnikov

Managing Director

Current

Anton Generalov

Managing Director

Current

Vasily Koshelev

Managing Director

Current

Name

Sergey V. Generalov

Maxim Likhachev

Eugene Andratchnikov

Anton Generalov

Vasily Koshelev

Work History

Title

President

Senior Vice President

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.